Movano (NASDAQ:MOVE) CFO Jeremy Cogan Sells 8,218 Shares of Stock

Movano Inc. (NASDAQ:MOVE) CFO Jeremy Cogan sold 8,218 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $7.79, for a total transaction of $64,018.22. Following the sale, the chief financial officer directly owned 15,107 shares in the company, valued at $117,683.53. This trade represents a 35.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Jeremy Cogan also recently made the following trade(s):

• On Monday, January 5th, Jeremy Cogan sold 1,879 shares of Movano stock. The shares were sold at an average price of $8.35, for a total transaction of $15,689.65.

Movano Price Performance

MOVE opened at $6.97 on Tuesday. The firm has a market capitalization of $5.79 million, a P/E ratio of -0.64 and a beta of 0.79. Movano Inc. has a one year low of $4.67 and a one year high of $58.76. The company has a fifty day moving average price of $8.82 and a 200-day moving average price of $7.57.

Movano (NASDAQ:MOVE) last posted its quarterly earnings data on Friday, November 14th. The technology company reported ($4.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.00) by $2.27. Movano had a negative return on equity of 647.91% and a negative net margin of 3,409.60%.The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $3.88 million.

Institutional Trading of Movano

A hedge fund recently bought a new stake in Movano stock. Citadel Advisors LLC purchased a new stake in shares of Movano Inc. (NASDAQ:MOVE) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 49,262 shares of the technology company’s stock, valued at approximately $28,000. Citadel Advisors LLC owned about 5.94% of Movano at the end of the most recent reporting period. 16.64% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Movano

Here are the key news stories impacting Movano this week:

• Positive Sentiment: Short interest fell in late December — as of Dec. 31 there were 43,438 shares short, a 29.1% decline from mid‑December, representing about 5.8% of the float and a low days‑to‑cover (0.5). Lower short interest can reduce downward short‑squeeze pressure.
• Neutral Sentiment: January short‑interest reporting appears inconsistent — an entry shows 0 shares (NaN change) as of Jan. 12, which looks like a data or reporting glitch and should be treated cautiously by traders.
• Negative Sentiment: Insiders selling — Movano’s CFO Jeremy Cogan disclosed two recent sales (1/5 and 1/6), including 8,218 shares on Jan. 6 at an average $7.79 and 1,879 shares on Jan. 5 at $8.35; these reduced his stake materially. See the SEC filing. Read More.
• Negative Sentiment: Additional insider selling — CTO Michael Aaron Leabman sold multiple tranches (Jan. 7–9) totaling several thousand shares at ~ $7.26–$7.34, trimming his holdings by mid‑single digits to low‑double digit percentages. Insider sales at these levels often weigh on small‑cap names with low liquidity. See the SEC filing. Read More.
• Negative Sentiment: Operational/financial context — Movano’s latest reported quarter (Nov. 14) showed a large EPS loss metric but a beat versus consensus; revenue was effectively negligible (~$0.08M vs. est. ~$3.9M) and margins/ROE were deeply negative. For investors, weak top‑line performance and very small revenue at a public company magnify execution and dilution risk.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Wall Street Zen raised shares of Movano to a “hold” rating in a research note on Saturday, December 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Movano in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Movano has a consensus rating of “Sell”.

About Movano

Movano Health, Inc (NASDAQ: MOVE) is a health technology company focused on developing wearable devices for continuous biometric monitoring. The company’s core mission is to provide accessible, real-time health insights through noninvasive sensors, enabling individuals and care teams to track vital signs and physiological trends outside of traditional clinical settings.

Movano’s flagship product is a biometric monitoring ring designed to measure parameters such as heart rate, blood oxygen saturation, skin temperature, and sleep quality.